Highlight Therapeutics Reports Positive Phase 2b Data for Intralesional BO-112 in Basal Cell Carcinoma
Positive Phase 2b topline results for intralesional BO-112 in localized basal cell carcinoma were presented as a late-breaker at the EADV Congress by Highlight Therapeutics.